GenMark Diagnostics, Inc. Description
GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the development, manufacturing, marketing, sale, and support of instruments and molecular tests based on its proprietary eSensor detection technology in the United States. The company's products include XT-8 system, an automated molecular diagnostic system that enables reference laboratories and hospitals to perform molecular diagnostic tests. It also offers 8 diagnostic tests for use with its XT-8 system that includes Cystic Fibrosis Genotyping Test, which detects a panel of mutations associated with cystic fibrosis; Warfarin Sensitivity test that determines an individual's ability to metabolize the oral anticoagulant warfarin; Thrombophilia Risk Test, which detects an individual's increased risk of blood clots; and Respiratory Viral Panel test that simultaneously detects and differentiates 14 clinically relevant viruses from patients with influenza-like illnesses. The company's diagnostic tests also include Hepatitis C Virus Genotyping test for the detection and typing/subtyping of HCV; 3A4/3A5 Genotyping test designed for the detection and genotyping of the alleles of the CYP450 3A4 gene locus and CYP450 3A5 gene locus; and 2C19 Genotyping test for the detection and genotyping alleles of the cytochrome P450 (CYP450) 2C19 gene locus. In addition, the company engages in developing a NexGen system to integrate automated nucleic acid extraction and amplification with its eSensor detection technology to enable technicians to place a patient sample into test cartridge and obtain results without any additional steps. Genmark Diagnostics, Inc. is headquartered in Carlsbad, California.
Hepatitis C Virus